CTLA4 and cancer: Despite the promising outcomes of anti-CTLA4 and anti-PD-1 antibodies in treating cancer, including solid tumors and hematopoietic malignancies,1,3,6,46 many of the treated patients do not respond well to the ICB, and those who initially do may not have durable clinical benefits.1